Dexamethasone Twice for Pain Treatment of Total Knee Arthroplasty
NCT ID: NCT03506789
Last Updated: 2020-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
485 participants
INTERVENTIONAL
2018-09-14
2020-06-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Dexamethasone as Analgesic Treatment After Total Knee Arthroplasty
NCT05008367
Dexamethasone and Pain Following Total Knee Arthroplasty
NCT02271698
Dexamethasone in Pain Control After Total Knee Replacement
NCT02767882
High-Dose Steroid for Knee Arthroplasty Patients Expected to Have Postoperative Pain
NCT03763734
Efficacy of Preoperative Intravenous Dexamethasone in Primary Total Knee Arthroplasty
NCT02102815
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Trial Acronym: DEX-2-TKA
Background: Effective postoperative pain management is essential for the well-being and rehabilitation of the surgical patient. No "gold standard" exists for pain treatment after total knee arthroplasty (TKA) since combinations of different analgesic treatments are used with nearly no evidence for combined analgesic efficacy. A single perioperative dose of glucocorticoid (GCC) (i.e. dexamethasone) has well established effects on postoperative nausea and vomiting, and may be beneficial for postoperative pain. A recent trial suggested that an additional postoperative dose of GCC improved postoperative pain treatment. Recent systematic reviews, sub-studies of RCTs and cohort studies of perioperative GCC raised no concern regarding serious adverse events of a single dose GCC for non-cardiac surgery. However, optimal dose, combination and regimen of perioperative GCC remains unsettled.
Objective: To establish the analgesic effect and safety of one and two consecutive days of a single dose of dexamethasone after TKA. GCC will be administered in combination with paracetamol, NSAID (ibuprofen), and local infiltration analgesia.
Intervention: The participants will be randomised in three groups: A) 24 mg dexamethasone i.v. perioperative (POD0) and 24 mg dexamethasone i.v. on the first postoperative day (POD1); B) 24 mg dexamethasone i.v. POD0 and placebo (isotonic saline) i.v. on POD1; and C) placebo i.v. on POD0 and POD1.
Design and trial size: Placebo-controlled, randomised, parallel 3-group multicentre trial with adequate centralised computer-generated allocation sequence and allocation concealment with unknown block size. Assessor, investigator, caregivers and participants will all be blinded. A total of 423 eligible participants are needed to detect a difference of 10 mg morphine for the first 48 hours postoperatively with a standard deviation of 23 mg, an overall familywise type 1 error rate of 0.05 and a type 2 error rate of 0.10. To compensate for uncertainty of the distribution a surplus of 15 % is added, thus a total of 486 patients will be included. To maintain an overall familywise error rate of 0.05 the sample size estimation is based on pairwise comparisons of the primary outcome between the three groups (three comparisons) with an individual type I error rate of 0.0167.
Sub studies: The investigators plan the following substudies
* One-year follow-up with EQ-5D-5L (EuroQuols - 5 dimension - 5 level score), Oxford-Knee-Score and mortality including need for medical attention.
* Troponin (TnI) levels 24 and 48 hours postoperatively (only at Naestved Hospital).
* Analysis of high and low pain responders.
* Establishment of a bio-bank (blood-samples) for future studies (only at Naestved Hospital).
Due to decisions made by the Steering Committee at our meeting the 14th of May 2019 in Køge, Region Zealand, Denmark, the secondary outcomes have been rearranged and divided into secondary outcomes and other (eksplorative) outcomes. Furthermore an additional explorative endpoint is added: Number of patients with a permanent use of opioids 90 days after surgery.
No data was unblinded or analyzed to aid the decisions.
After the last patient was included, but prior to data analysis and unmasking, the Steering Committee decided to include the following explorative outcomes in the main article reporting results from this trial. The decision was made by consensus via email 4th of October 2020:
* proportion of participants with one or more severe adverse event (SAE), including death, within 90 days after surgery (SAE defined according to ICH-GCP-guidelines, except 'prolongation of hospitalisation')
* opioid related adverse events (AE)
* level of nausea, sedation and dizziness at 24 and 48 h
* number of vomiting episodes 0-24 and 24-48 h"
* use of anti-emetics 0-24 and 24-48 h
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment A:
24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
Dexamethasone
Dexamethasone 24 mg
Treatment B:
24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
Dexamethasone
Dexamethasone 24 mg
Placebos
Isotonic saline
Placebo
Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
Placebos
Isotonic saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone
Dexamethasone 24 mg
Placebos
Isotonic saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA 1-3
* BMI ≥ 18.0 and ≤ 40.0
* Negative urine HCG pregnancy test and use of anti-conception for women in the fertile age
* Patients who gave their written informed consent to participating in the trial after having fully understood the contents of the protocol and restrictions
Exclusion Criteria
* Concomitant participation in another trial involving medication
* Patients who cannot understand or speak Danish
* Patients with allergy to medication used in the trial
* Patients with daily use of high dose opioid (\> oral morphine 30 mg/day or oxycodone 30 mg/day or tramadol 150 mg/day) or any use of other opioids including methadone and transdermal opioids.
* Patients with at daily use of systemic glucocorticoids
* Contraindications against ibuprofen or paracetamol, for example previous ulcer, known heart failure, known liver failure, or known renal failure (eGRF \< 60 ml/kg/1,73m2), known thrombocytopenia (\<100 bil/l); or against treatment with glucocorticoids.
* Dysregulated diabetes (investigators judgement)
* Patients suffering from alcohol and/or drug abuse - based on the investigator's judgement
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Naestved Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ole Mathiesen, MD, PhD, Assoc Prof
Role: STUDY_CHAIR
Department of Anaesthesiology, Zealand University Hospital, Køge
Daniel Hägi-Pedersen, MD, PhD
Role: STUDY_CHAIR
Department of Anaesthesiology, Næstved Hospital
Jørgen B Dahl, DMSc
Role: STUDY_CHAIR
Department of Anaesthesiology, Bispebjerg Hospital
Kasper S Gasbjerg, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Anaesthesiology, Næstved Hospital
Troels H Lunn, DMSc
Role: STUDY_CHAIR
Department of Anaesthesiology, Bispebjerg Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gildhøj Privathospital
Brøndby, , Denmark
Bispebjerg Hospital
Copenhagen, , Denmark
Sjællands Universitetshospital, Køge
Køge, , Denmark
Næstsved Sygehus
Næstved, , Denmark
Odense Universitetshospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Molgaard AK, Gasbjerg KS, Mathiesen O, Hagi-Pedersen D, Gogenur I. Dexamethasone vs. placebo modulation of the perioperative blood immune proteome in patients undergoing total knee arthroplasty. BMC Anesthesiol. 2025 Mar 21;25(1):136. doi: 10.1186/s12871-025-03003-3.
Derby CB, Gasbjerg KS, Hagi-Pedersen D, Lunn TH, Pedersen NA, Lindholm P, Brorson S, Schroder HM, Thybo KH, Bagger J, Lindberg-Larsen M, Overgaard S, Jakobsen JC, Mathiesen O. Prolonged effects of dexamethasone following total knee arthroplasty: A pre-planned sub-study of the DEX-2-TKA trial. Acta Anaesthesiol Scand. 2024 Jan;68(1):35-42. doi: 10.1111/aas.14319. Epub 2023 Sep 14.
Gasbjerg KS, Hagi-Pedersen D, Lunn TH, Laursen CC, Holmqvist M, Vinstrup LO, Ammitzboell M, Jakobsen K, Jensen MS, Pallesen MJ, Bagger J, Lindholm P, Pedersen NA, Schroder HM, Lindberg-Larsen M, Norskov AK, Thybo KH, Brorson S, Overgaard S, Jakobsen JC, Mathiesen O. Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial. BMJ. 2022 Jan 4;376:e067325. doi: 10.1136/bmj-2021-067325.
Gasbjerg KS, Hagi-Pedersen D, Lunn TH, Overgaard S, Pedersen NA, Bagger J, Lindholm P, Brorson S, Schroder HM, Thybo KH, Mathiesen O, Jakobsen JC. DEX-2-TKA - DEXamethasone twice for pain treatment after Total Knee Arthroplasty: Detailed statistical analysis plan for a randomized, blinded, three-group multicentre clinical trial. Acta Anaesthesiol Scand. 2020 Jul;64(6):839-846. doi: 10.1111/aas.13560. Epub 2020 Mar 3.
Gasbjerg KS, Hagi-Pedersen D, Lunn TH, Jakobsen JC, Overgaard S, Pedersen NA, Bagger J, Lindholm P, Brorson S, Schroder HM, Thybo KH, Mathiesen O. DEX-2-TKA-DEXamethasone twice for pain treatment after Total Knee Arthroplasty: A protocol for a randomized, blinded, three-group multicentre clinical trial. Acta Anaesthesiol Scand. 2020 Feb;64(2):267-275. doi: 10.1111/aas.13481. Epub 2019 Oct 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SM1-KAKG-2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.